To align with industry best practices for security and data integrity, Project Data Sphere is requiring users to upgrade their browsers to one that supports encryption protocol TLS 1.2 by December 15, 2017. On that date, Project Data Sphere will disable support of browsers that permit SSL 3.0/TLS 1.0. To prevent any disruption to your access to Project Data Sphere, you must take action. This browser was not recognized and may not be compatible with TLS 1.2 or higher. Please check with the browser's developer to confirm. To view information about this, please visit the FAQ. If you have any further questions, please contact us.
ASSURE: Adjuvant Sorafenib or Sunitinib for Unfavorable Renal Carcinoma
Provider Data DescriptionAs of November 6, 2017, there are four different datasets available for NCT00326898. This is NCT00326898-D4. NCT00326898-D1 and NCT00326898-D3 each contain the same clinical data. NCT00326898-D2 and NCT00326898-D4 each contain the same toxicity data. NCT00326898-D1 and NCT00326898-D2 were the original two submissions. NCT00326898-D3 and NCT00326898-D4 updated the original data submissions to include a new blinded ID that will allow for the future linking to non-clinical data (e.g., genomic data). Other than the IDs, the datasets are identical. We recommend that NCT00326898-D3 and NCT00326898-D4 be used.
SponsorNational Cancer Institute
Data ProviderNational Cancer Institute
Clinical Trials.gov Information
Brief SummaryThis randomized phase III trial studies sunitinib malate to see how well it works compared to sorafenib tosylate or placebo in treating patients with kidney cancer that has been removed by surgery. Sunitinib malate and sorafenib tosylate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor. Giving sunitinib malate or sorafenib tosylate after surgery may kill any tumor cells that remain after surgery. It is not yet known whether sunitinib malate is more effective than sorafenib tosylate or placebo in treating kidney cancer.
ConditionsClear Cell Renal Cell Carcinoma Stage I Renal Cell Cancer AJCC v6 and v7 Stage II Renal Cell Cancer AJCC v7 Stage III Renal Cell Cancer AJCC v7